share_log

HC Wainwright & Co. Maintains Buy on BioLine Rx, Raises Price Target to $21

HC Wainwright & Co. Maintains Buy on BioLine Rx, Raises Price Target to $21

HC Wainwright & Co.维持对BioLine Rx的买入,将目标价上调至21美元
Benzinga ·  2023/09/15 06:11

HC Wainwright & Co. analyst Joseph Pantginis maintains BioLine Rx (NASDAQ:BLRX) with a Buy and raises the price target from $19 to $21.

HC Wainwright & Co. 分析师约瑟夫·潘吉尼斯将BioLine Rx(纳斯达克股票代码:BLRX)维持买入,并将目标股价从19美元上调至21美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发